Literature DB >> 9005145

Medullary thyroid cancer: the role of radiotherapy in local control.

K M Fife1, M Bower, C L Harmer.   

Abstract

Fifty-one patients were treated with radiotherapy for loco-regional medullary thyroid cancer between 1960-1992. The actuarial overall survival at 5, 10 and 20 years was 69%, 52% and 30%, respectively. Patients were classified according to clinical stage (node-positive or -negative), post-operative histological residual disease status (none, microscopic or macroscopic) and dose of radiotherapy received. By univariate analysis, loco-regional recurrence-free survival was significantly longer for node-negative patients (P = 0.03). Patients who received at least 60 Gy over 6 weeks showed a trend towards improved local control (P = 0.23). The only significant variable by multivariate analysis for local recurrence-free survival was post-operative residual disease status (P=0.0005). The local control rate at 5 years was 100% for patients with no residual disease, 65% for those with microscopic tumour, and 24% for those with macroscopic residual disease. We conclude that there is a valuable role for radiotherapy in the management of patients with residual microscopic or macroscopic disease following surgery, as well as in those with inoperable disease.

Entities:  

Mesh:

Year:  1996        PMID: 9005145     DOI: 10.1016/s0748-7983(96)92294-5

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  13 in total

1.  Adjuvant external beam radiation for medullary thyroid carcinoma.

Authors:  Steve R Martinez; Shannon H Beal; Allen Chen; Steven L Chen; Philip D Schneider
Journal:  J Surg Oncol       Date:  2010-08-01       Impact factor: 3.454

2.  Prognostic factors for sporadic medullary thyroid carcinoma.

Authors:  Kaptan Gülben; Uğur Berberoğlu; Mustafa Boyabatli
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

Review 3.  Surgical management of medullary thyroid carcinoma.

Authors:  Agathoklis Konstantinidis; Michael Stang; Sanziana A Roman; Julie Ann Sosa
Journal:  Updates Surg       Date:  2017-04-13

Review 4.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

5.  Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry.

Authors:  P Lennon; S Deady; N White; D Lambert; M L Healy; A Green; J Kinsella; C Timon; J P O' Neill
Journal:  Ir J Med Sci       Date:  2016-04-15       Impact factor: 1.568

6.  Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma.

Authors:  Andries H Groen; Thomas H Beckham; Thera P Links; Debra A Goldman; Eric J Sherman; Michael M Tuttle; Hendrik P Bijl; Richard J Wong; John Th M Plukker; Nancy Y Lee
Journal:  J Surg Oncol       Date:  2019-11-16       Impact factor: 3.454

Review 7.  Medullary thyroid cancer.

Authors:  E Kebebew; O H Clark
Journal:  Curr Treat Options Oncol       Date:  2000-10

8.  Evaluation of Survival and Postoperative Radiation Among Patients with Advanced Medullary Thyroid Carcinoma: An Analysis of the National Cancer Database.

Authors:  Thomas J Ow; Vikas Mehta; Seokhwa Kim; Mayand Vakil; Patricia Friedmann; Haejin In
Journal:  Ann Surg Oncol       Date:  2022-01-23       Impact factor: 5.344

9.  Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).

Authors:  M Nocera; E Baudin; G Pellegriti; A F Cailleux; C Mechelany-Corone; M Schlumberger
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

Review 10.  Multiple endocrine neoplasia type 2.

Authors:  Michael E Gertner; Electron Kebebew
Journal:  Curr Treat Options Oncol       Date:  2004-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.